Cargando…
Ritlecitinib: First Approval
Ritlecitinib (LITFULO(™)), an orally administered kinase inhibitor, is being developed by Pfizer for the treatment of alopecia areata, vitiligo, ulcerative colitis and Crohn’s disease. On 23 June 2023, ritlecitinib received approval in the USA for the treatment of severe alopecia areata in adults an...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556173/ https://www.ncbi.nlm.nih.gov/pubmed/37556041 http://dx.doi.org/10.1007/s40265-023-01928-y |